TORONTO – The Canadian distributor of the EpiPen says there is a shortage of one size of the emergency treatment for people at risk of life-threatening allergic reactions.
Pfizer Canada says there is a shortage of the 0.3-milligram form of the EpiPen (DIN 00509558) because of a manufacturing disruption. The 0.15-mg EpiPen Jr product for young children is not affected.
The company anticipates the shortfall in supply will be resolved by March 2.
It says additional limited inventory will be available at the beginning of February, but will be carefully managed.
EpiPens expire on the last day of the month indicated on the product packaging. But Health Canada advises anyone having an anaphylactic reaction to use their expired product and immediately call 911.
Pfizer is asking pharmacists to keep the supply interruption in mind when filling prescriptions, as there are currently no alternative auto-injectors available on the Canadian market.
-
![]()
Raising awareness about dairy allergies -
![]()
Edmonton program challenges allergies through tests -
![]()
Teal Pumpkin Project offers safe Halloween for children with allergies -
![]()
Traveling with allergies -
![]()
Lone Star ticks that cause red meat allergies are on their way to Canada -
![]()
Are allergies worse than normal this year?
“At this time, there is limited supply of auto-injectors at wholesalers, distributors and at pharmacies,” the drug maker said on its website.
“While we are working closely with our distributors to avoid long-term supply shortage at the store level, we expect a period of between two and four weeks of no inventory.”
Comments